To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Absorbed Doses and Risk E… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.

Journal article
Authors Elin Cederkrantz
Håkan Andersson
Peter Bernhardt
Thomas Backhaus
Ragnar Hultborn
Lars Jacobsson
Holger Jensen
Sture Lindegren
Michael Ljungberg
Tobias Magnander
Stig Palm
Per Albertsson
Published in International journal of radiation oncology, biology, physics
Volume 93
Issue 3
Pages 569-76
ISSN 1879-355X
Publication year 2015
Published at Institute of Clinical Sciences, Department of Radiation Physics
Institute of Clinical Sciences, Department of Oncology
Department of Biological and Environmental Sciences
Pages 569-76
Language en
Subject categories Cancer and Oncology, Radiological physics


Ovarian cancer is often diagnosed at an advanced stage with dissemination in the peritoneal cavity. Most patients achieve clinical remission after surgery and chemotherapy, but approximately 70% eventually experience recurrence, usually in the peritoneal cavity. To prevent recurrence, intraperitoneal (i.p.) targeted α therapy has been proposed as an adjuvant treatment for minimal residual disease after successful primary treatment. In the present study, we calculated absorbed and relative biological effect (RBE)-weighted (equivalent) doses in relevant normal tissues and estimated the effective dose associated with i.p. administration of (211)At-MX35 F(ab')2.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?